Examples of using Decrease in haemoglobin in English and their translations into Norwegian
{-}
-
Colloquial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Decrease in haemoglobin in your blood.
That treatment with STAYVEER is associated with a decrease in haemoglobin.
G/dL decrease in haemoglobin during any.
TIMI Minor Bleed: Clinically apparent with 30 50 g/l decrease in haemoglobin.
Decrease in haemoglobin and in haematocrit.
That treatment with Volibris often causes a decrease in haemoglobin and haematocrit.
Decrease in haemoglobin in your blood low red blood cell count.
None of these changes were associated with bleeding episodes or a decrease in haemoglobin.
G/dL decrease in haemoglobin during any 4 week treatment period.
That treatment with Thelin often causes a decrease in haemoglobin and related red cell parameters.
Decrease in haemoglobin(oxygen-carrying pigment in blood) and leukocytes white blood cells.
TIMI Major Bleed: Clinically apparent with>50 g/L decrease in haemoglobin or intracranial haemorrhage.
G/dL decrease in haemoglobin during any 4 week period during treatment permanent dose reduction.
Macitentan may lead to more reduction of blood pressure and decrease in haemoglobin in patients with kidney problems.
If a clinically significant decrease in haemoglobin or haematocrit is observed, and other causes have been excluded, dose reduction or discontinuation of treatment should be considered.
PLATO Major Fatal/life-threatening: Fatal bleeding, OR any intracranial bleeding, OR intrapericardial with cardiac tamponade, OR with hypovolaemic shock or severe hypotension requiring pressors/inotropes or surgery OR clinically apparent with>50 g/L decrease in haemoglobin or≥4 red cell units transfused.
That Tracleer causes a decrease in haemoglobin and the need for regular blood tests.
Decrease in haemoglobin, decrease in haematocrit, neutropenia, thrombocytopenia, increase of serum potassium, elevation of liver function values including increase of serum bilirubin, renal failure and impairment, elevation of serum creatinine, angioedema, myalgia, vasculitis, hypersensitivity including serum sickness.
Medicinaltreated with irbesartan, a decrease in haemoglobin*, which was not clinically significant, has been observed.
That STAYVEER causes a decrease in haemoglobin and the need for regular blood tests.
Major Other: Clinically apparent with 30-50 g/l decrease in haemoglobin or 2-3 red cell units transfused; or significantly disabling.
Dry mouth low white blood cell and/or platelet count, decrease in haemoglobin in your blood, increase in triglycerides, lipase and/or bilirubin in your blood.
If tests show a clinically significant decrease in haemoglobin or haematocrit, and other causes have been excluded, consider reducing the dose of Volibris, or stopping treatment.
Major Fatal/Life-threatening Bleed: Clinically apparent with>50 g/l decrease in haemoglobin or≥4 red cell units transfused; or fatal; or intracranial; or intrapericardial with cardiac tamponade; or with hypovolaemic shock or severe hypotension requiring pressors or surgery.
Decreases in haemoglobin, neutrophils and platelets may require dose reduction or permanent discontinuation from treatment see Table 3 and Table 7.
Decreases in haemoglobin, white blood cells, platelets, neutrophils and increase in bilirubin may require dose reduction or permanent discontinuation from therapy see section 4.2.
Decreases in haemoglobin to< 10 g/dL and< 8.5 g/dL during treatment were experienced by 39% and 13% of patients treated with ledipasvir/sofosbuvir with ribavirin, respectively.